HYPERTONIA ÉS NEPHROLOGIA - eLitMed.hu

18 MARKUS KETTELER HYPERTONIA ÉS NEPHROLOGIA
14. Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, Rumberger J, Stanford W, White R, Taubert K (1996) Coronary artery
calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American
Heart Association. Writing Group. Circulation 94:1175-1192.
15. Wayhs R, Zelinger A, Raggi P (2002) High coronary artery calcium scores pose an extremely elevated risk for hard events. J Am Coll Cardiol
39:225-230.
16. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K (2000) Morphology of coronary atherosclerotic lesions in patients
with end-stage renal failure. Nephrol Dial Transplant 15:218-223.
17. Beckman JA, Ganz J, Creager MA, Ganz P, Kinlay S (2001) Relationship of clinical presentation and calcification of culprit coronary artery
stenoses. Arterioscler Thromb Vasc Biol 21:1618-1622.
18. Huang H, Virmani R, Younis H, Burke AP, Kamm RD, Lee RT (2001) The impact of calcification on the biomechanical stability of atherosclerotic
plaques. Circulation 103:1051-1056.
19. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H (2002) Arterial structure and function in end-stage renal disease. Nephrol Dial
Transplant 17:1713-1724.
20. London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F, Chedid K, London AM (1990) Aortic and large artery compliance in
end-stage renal disease. Kidney Int. 37:137-142.
21. Blacher J, Guerin AP, Pannier B., Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage
renal disease. Hypertension 38:938-942.
22. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM (2002) Cardiac calcification in adult hemodialysis patients. A link
between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695-701.
23. Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
Kidney Int 62:245-252.
24. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ (1998) Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by
electron-beam computed tomography. N Engl J Med 339:1972-1978.
25. Wilkes BM, Reiner D, Kern M, Burke S (1998) Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride
(RenaGel) in dialysis patients. Clin Nephrol 50:381-386.
26. Chertow GM, Burke SK, Dillon MA, Slatopolsky E (1999) Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and
lipid profile of haemodialysis patients. Nephrol Dial Transplant 14:2709-2714.
27. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM (2000) Phosphate regulation of vascular smooth muscle cell
calcification. Circ Res 87:E10-17.
28. Moe SM, O’Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K (2002) Medial artery calcification in ESRD patients is
associated with deposition of bone matrix proteins. Kidney Int 61:638-647.
29. Moe SM, Duan D, Doehle BP, O’Neill KD, Chen NX (2003) Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels.
Kidney Int 63:1003-1011.
30. Ketteler M, Wanner C, Metzger T, Bongartz P, Westenfeld R, Gladziwa U, Schurgers LJ, Vermeer C, Jahnen-Dechent W, Floege J (2003)
Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia. Kidney Int Suppl
84:S84-S87.
31. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice
lacking matrix GLA protein. Nature 386:78-81.
32. Munroe PB, Olgunturk RO, Fryns JP, Van Maldergem L, Ziereisen F, Yuksel B, Gardiner RM, Chung E (1999) Mutations in the gene encoding the
human matrix Gla protein cause Keutel syndrome. Nat Genet 21:142-144.
33. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL (1994) High expression of genes for calcification-regulating proteins in human
atherosclerotic plaques. J Clin Invest 93:2393-2402.
34. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W (1996) The serum protein alpha2-HS glycoprotein/fetuin inhibits
apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem
271:20789-20796.
35. Jahnen-Dechent W, Schinke T, Trindl A, Muller-Esterl W, Sablitzky F, Kaiser S, Blessing M (1997) Cloning and targeted deletion of the mouse
fetuin gene. J Biol Chem 272:31496-31503.
36. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G (1979) Serum concentration of human alpha 2 HS glycoprotein during the
inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 64:1118-1129.
37. Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, Renne T, Jahnen-Dechent W (2003) Structural basis of calcification inhibition by
alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 278:13333-13341.
38. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W (2003) The serum protein
alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112:357-366.
39. Price PA, Nguyen TM, Williamson MK (2003) Biochemical characterization of the serum fetuin-mineral complex. J Biol Chem
278:22153-22160.
40. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J (2003)
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet
361:827-833.